Skip to main content
. 2017 Dec 19;318(23):2306–2316. doi: 10.1001/jama.2017.18718

Figure 4. Overall Survival by Patient Age and by MGMT Promotor Region Methylation Status.

Figure 4.

A, In comparing tumor-treating fields (TTFields) plus temozolomide vs temozolomide alone among patients younger than 65 years the hazard ratio (HR) was 0.67 (95% CI, 0.55-0.82). B, In comparing the 2 treatments among patients 65 years or older, the HR was 0.51 (95% CI, 0.22-0.77). C, In comparing the treatments among patients with O6-methylguanine-DNA methyltransferase MGMT promotor region methylation, the HR was 0.62 (95% CI, 0.43-0.88). D, In comparing the treatments among patients without the MGMT promotor region methylation, the HR was 0.66 (95% CI, 0.49-0.85). The median follow-up of patients was 44 months (range, 25-91 months) in all groups.